0000000000266724

AUTHOR

John R. Mackey

showing 4 related works from this author

Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.

2010

Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patie…

OncologyMaleSettore MED/06 - Oncologia MedicaPhysiologymedicine.medical_treatmentClinical BiochemistryNucleoside transporterEquilibrative nucleoside transporter 1Cohort StudiesMedicineNeoplasm MetastasisAged 80 and overbiologyMiddle AgedPrognosisImmunohistochemistryFludarabineSurvival RateDisease ProgressionFemalemedicine.drugAdultmedicine.medical_specialtyNucleoside transporterAntineoplastic AgentsAdenocarcinomaDisease-Free SurvivalEquilibrative Nucleoside Transporter 1Predictive Value of TestsStomach NeoplasmsPancreatic cancerInternal medicineBiomarkers TumorHumansSurvival rateAgedRetrospective Studiesbusiness.industryCancerCell Biologymedicine.diseaseGemcitabineRadiation therapyDrug Resistance NeoplasmGastric MucosaImmunologybiology.proteinNeoplasm Recurrence LocalbusinessJournal of cellular physiology
researchProduct

The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtyp…

2013

1031 Background: According to observational studies, obesity is an unfavourable prognostic factor in breast cancer (BC), regardless of menopausal status and treatment received. Information collected in clinical trials should confirm this effect and serves to test its homogeneity by pathologic subtype. Methods: We retrospectively analysed 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, 9805, 2003–02, and BCIRG 001) evaluating adjuvant anthracyclines and taxanes. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differ…

GynecologyOncologyCancer Researchmedicine.medical_specialtyPrognostic factorbusiness.industrymedicine.medical_treatmentmedicine.diseaseObesityBreast cancerOncologyInternal medicinemedicineObservational studybusinessAdjuvantJournal of Clinical Oncology
researchProduct

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

2009

Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were…

Oncologymedicine.medical_specialtyPathologyCancer ResearchAntimetabolites Antineoplasticmedicine.medical_treatmentEquilibrative nucleoside transporter 1DeoxycytidineEquilibrative Nucleoside Transporter 1Statistical significanceInternal medicineDrug DiscoveryMedicineHumansHENT1PharmacologyChemotherapyUnivariate analysisPredictive markerBiliary tract cancer; Gemcitabine; HENT1; Predictive factor; Drug Discovery3003 Pharmaceutical Science; Pharmacology; Cancer Researchbiologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCancermedicine.diseaseImmunohistochemistryGemcitabineGemcitabineBiliary Tract NeoplasmsOncologybiology.proteinImmunohistochemistryBiliary tract cancerbusinessPredictive factormedicine.drug
researchProduct

Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled…

2013

Obesity is an unfavorable prognostic factor in breast cancer (BC) patients regardless of menopausal status and treatment received. However, the association between obesity and survival outcome by pathological subtype requires further clarification. METHODS: We performed a retrospective analysis including 5,683 operable BC patients enrolled in four randomized clinical trials (GEICAM/9906, GEICAM/9805, GEICAM/2003-02, and BCIRG 001) evaluating anthracyclines and taxanes as adjuvant treatments. Our primary aim was to assess the prognostic effect of body mass index (BMI) on disease recurrence, breast cancer mortality (BCM), and overall mortality (OM). A secondary aim was to detect differences o…

Índice de Masa CorporalOncologyReceptor ErbB-2medicine.medical_treatmentObesidad:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis [Medical Subject Headings]Supervivencia sin EnfermedadBody Mass IndexAntineoplastic Combined Chemotherapy ProtocolsMedicineAnthracyclinesYoung adultMedicine(all)Hazard ratioNeoplasias de la MamaPronósticoFemeninoMiddle AgedPrognosisChemotherapy regimenTreatment OutcomeFemaleTaxoidsMastectomyResearch ArticleAdultmedicine.medical_specialtyAnálisis de Supervivencia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]Breast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAdjuvant therapyHumansObesity:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Disease-Free Survival [Medical Subject Headings]:Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms [Medical Subject Headings]AgedGynecologyDose-Response Relationship Drugbusiness.industry:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [Medical Subject Headings]Retrospective cohort studyAntineoplásicosmedicine.disease:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]:Check Tags::Female [Medical Subject Headings]Multivariate Analysis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis [Medical Subject Headings]Neoplasm Recurrence LocalbusinessBody mass index
researchProduct